This World Alzheimer’s Month, early career researchers from across the UK and beyond have been hard at work harnessing data science and AI to solve real life problems in dementia and health research. Data Study Groups are ‘collaborative hackathon’ style events organised by The Alan Turing Institute, and the September 2021 event featured dementia challenges set by the UK DRI in collaboration with the DEMON Network. We found out more about the projects these data scientists embarked upon and the innovative solutions they have uncovered.
The Turing Data Study Groups are events that bring together data scientists and AI to tackle data driven research challenges set by organisations – the ‘Challenge Owners’. Importantly, the challenges use real-life data, so that the results of the Data Study Groups can have real-world impact. The Turing Data Study Groups aim to bring the power of computational approaches to bear on problems in research areas that may not have traditionally used data science and AI. Previous organisations who have taken part include partner universities like the University of Bristol and Siemens Global Centre of Competence Cities. Challenges posed range from how to automatically identify proteins from cryogenic electron microscopy images to how urban infrastructure can be optimised to reduce air pollution. Many of these Challenge Owners have continued to collaborate with The Alan Turing Institute and the researchers involved in the Data Study Groups.
Finding innovative ways to approach research is important to drive ground-breaking advances in this area and develop new technologies and treatments. The Turing Data Study Groups provided a fantastic opportunity to develop and test possible solutions to a variety of problems encountered in dementia research that required the computational skills of talented groups of researchers to solve. The challenges posed are described below:
Modelling amyloid beta protein plaque formation in Alzheimer’s disease
Prof Bart De Strooper (UK DRI Director) and Dr Mark Fiers (VIB-KU Leuven)
Amyloid beta protein plaques are a hallmark of Alzheimer’s disease and are thought to be associated with disease progression. The plaques exist in different shapes; however, it isn’t known whether or not these shapes have different effects on the surrounding cells in the brain. Establishing this link with image analysis and machine learning methods could help guide potential treatments that target amyloid plaques, maximising their benefit by focussing on the most harmful plaques.
Predicting functional relationships between DNA sequence and epigenetic state: Can computational models consider important genomic variants?
Dr Nathan Skene (UK DRI at Imperial)
Current deep learning models can determine where DNA will bind regulatory proteins and its likely epigenetic state at that region. However, these models are based on a single reference genome, so it isn’t known how the accuracy of the models is affected by variants that exist in different genomes. Validating that these models can take into account genetic variants will allow them to predict how such variants associated with Alzheimer’s contribute to the disease mechanism through epigenetics. This could help identify important molecular and cellular steps in the disease as potential therapeutic targets.
As Dr Skene explained further:
“Our group are trying to establish which of the millions of genetic variants common in humans affect neurodegenerative diseases and how. This is impractical to study experimentally, so we’ve proposed a project to find the genetic variant effects computationally using machine learning.”
Using machine learning to improve sleep habits in people living with dementia
Dr Eyal Soreq, Prof Payam Barnaghi and Prof David Sharp (UK DRI at CR&T)
Sleep disorders can be a problem for people with dementia. By using data from multiple sensors that recorded the sleep patterns and conditions of people living with dementia, the project aims to identify how sleep metrics are affected by changes in different conditions, and determine if models can suggest condition changes that could improve sleep quality.
challenges set by the UK DRI and the DEMON Network
I feel that we should strive for more events like these in the future, since they will help us to look beyond the day-to-day challenges to the horizon of possibilities.Dr Eyal SoreqUK DRI at Care Research and Technology
Following preparations, the Data Study Group ran from 6-24 September with the participant researchers working alongside Challenge Owners and Principal Investigators – early career researchers who support the Challenge Owners to prepare the challenge. The Data Study Group culminated with the presentations from the teams on 24 September, where the researchers explained their approaches and findings to the challenges set.
On the results of the challenge, Dr Soreq, said:
“I was very impressed by the study's proposed directions on some of the issues we face at the Care Research and Technology Centre, specifically when developing different methods to objectively monitor people living with dementia using sensors in their homes. The study has given us the fresh perspective we hoped for when we approached the Turing challenge, and I am very eager to examine the final report. I feel that we should strive for more events like these in the future, since they will help us to look beyond the day-to-day challenges to the horizon of possibilities.”
Regarding the Turing Data Study Groups, Dr Skene also said:
“The Data Study Groups appealed to me because AI researchers would consider novel and cutting-edge AI approaches to the problem. The work done by the team has led us to consider fresh angles on the analysis of our data. Members of our Data Study Group team threw themselves into the project, grasped the biological issues rapidly and built a strong rapport: several have now said they are keen to continue tackling the project after the event.”
These data study groups are one example of how data science is transforming modern research. With a health challenge as large as dementia, making use of data-driven approaches will help accelerate our progress to find new technologies and treatments for neurodegenerative disease.
Find out more about how to get involved with Data Study Groups, as a Challenge Owner, Principal Investigator or participant.
Article published: 30 September 2021